Read More: eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient


Jennifer Bergheiser

Chief Business Officer
  • LinkedIn

Ms. Bergheiser brings over 20 years of experience in the biopharmaceutical sector across strategy and new product planning at large and small biopharma as well as venture investing, and management consulting. Her experience spans product modalities and numerous therapeutic areas. On the operating side, at Centocor/Johnson & Johsnson, Ms. Bergheiser oversaw commercial product development, market development and lifecycle management for blockbuster injectable therapy Stelara® as well as additional biologics in development for various autoimmune indications. At Acureon Pharmaceuticals, Ms. Bergheiser led strategy and business development for a venture-backed start-up in the anti-infectives arena.

Prior to transitioning to the operating side, Ms. Bergheiser served in venture capital at Domain Associates, heading up screening and evaluation of new investment opportunities for the firm as well as supporting select portfolio companies on strategy and business development. She supported investments in several companies that resulted in liquidity events for the firm: ESP Pharma, Peninsula Pharmaceuticals, and Proxima Therapeutics. Ms. Bergheiser served as an observer on the boards of TargetRx and Proxima Therapeutics.

Ms. Bergheiser began her career in management consulting, within the Pharmaceutical and Medical Products Strategy practice of Accenture, supporting large pharmaceutical clients across the areas of new product launch, organizational design, and pricing and market access.

Ms. Bergheiser holds a Masters in Business Administration from The Wharton School of Business and Bachelors Degrees in Economics, History from the University of Pennsylvania.

Jennifer Bergheiser